Compare IPCA Labs with Aurobindo Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

IPCA LABS vs AUROBINDO PHARMA - Comparison Results

IPCA LABS     Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

AUROBINDO PHARMA 
   Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    IPCA LABS AUROBINDO PHARMA IPCA LABS/
AUROBINDO PHARMA
 
P/E (TTM) x 23.6 18.4 128.3% View Chart
P/BV x 8.4 4.0 212.0% View Chart
Dividend Yield % 0.1 0.3 54.3%  

Financials

 IPCA LABS   AUROBINDO PHARMA
EQUITY SHARE DATA
    IPCA LABS
Mar-19
AUROBINDO PHARMA
Mar-19
IPCA LABS/
AUROBINDO PHARMA
5-Yr Chart
Click to enlarge
High Rs1,042830 125.5%   
Low Rs590527 112.0%   
Sales per share (Unadj.) Rs298.6333.9 89.4%  
Earnings per share (Unadj.) Rs35.040.4 86.7%  
Cash flow per share (Unadj.) Rs49.451.8 95.5%  
Dividends per share (Unadj.) Rs3.002.50 120.0%  
Dividend yield (eoy) %0.40.4 99.8%  
Book value per share (Unadj.) Rs247.1237.1 104.2%  
Shares outstanding (eoy) m126.35585.91 21.6%   
Bonus/Rights/Conversions ESOSESOP-  
Price / Sales ratio x2.72.0 134.5%   
Avg P/E ratio x23.316.8 138.7%  
P/CF ratio (eoy) x16.513.1 125.9%  
Price / Book Value ratio x3.32.9 115.4%  
Dividend payout %8.66.2 138.4%   
Avg Mkt Cap Rs m103,108397,569 25.9%   
No. of employees `00013.417.9 75.3%   
Total wages/salary Rs m7,87425,849 30.5%   
Avg. sales/employee Rs Th2,807.010,956.9 25.6%   
Avg. wages/employee Rs Th585.81,447.7 40.5%   
Avg. net profit/employee Rs Th329.01,324.3 24.8%   
INCOME DATA
Net Sales Rs m37,732195,636 19.3%  
Other income Rs m5771,553 37.1%   
Total revenues Rs m38,309197,189 19.4%   
Gross profit Rs m6,90139,519 17.5%  
Depreciation Rs m1,8246,680 27.3%   
Interest Rs m1892,626 7.2%   
Profit before tax Rs m5,46531,767 17.2%   
Minority Interest Rs m027 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-881 0.0%   
Tax Rs m1,0427,269 14.3%   
Profit after tax Rs m4,42223,645 18.7%  
Gross profit margin %18.320.2 90.5%  
Effective tax rate %19.122.9 83.4%   
Net profit margin %11.712.1 97.0%  
BALANCE SHEET DATA
Current assets Rs m23,778153,645 15.5%   
Current liabilities Rs m10,975120,429 9.1%   
Net working cap to sales %33.917.0 199.8%  
Current ratio x2.21.3 169.8%  
Inventory Days Days104135 76.7%  
Debtors Days Days6664 103.5%  
Net fixed assets Rs m20,368103,909 19.6%   
Share capital Rs m253586 43.1%   
"Free" reserves Rs m30,971138,322 22.4%   
Net worth Rs m31,224138,908 22.5%   
Long term debt Rs m1,4091,800 78.3%   
Total assets Rs m45,507264,544 17.2%  
Interest coverage x30.013.1 228.7%   
Debt to equity ratio x00 348.2%  
Sales to assets ratio x0.80.7 112.1%   
Return on assets %10.19.9 102.0%  
Return on equity %14.217.0 83.2%  
Return on capital %17.323.8 72.7%  
Exports to sales %45.949.6 92.4%   
Imports to sales %16.618.8 88.4%   
Exports (fob) Rs m17,30897,091 17.8%   
Imports (cif) Rs m6,26636,741 17.1%   
Fx inflow Rs m17,30897,316 17.8%   
Fx outflow Rs m6,26640,589 15.4%   
Net fx Rs m11,04256,727 19.5%   
CASH FLOW
From Operations Rs m4,92316,220 30.3%  
From Investments Rs m-1,563-28,768 5.4%  
From Financial Activity Rs m-1,83219,191 -9.5%  
Net Cashflow Rs m1,5286,656 23.0%  

Share Holding

Indian Promoters % 45.9 54.1 84.8%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 11.4 8.0 143.4%  
FIIs % 25.3 27.7 91.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.4 10.2 170.6%  
Shareholders   36,892 69,601 53.0%  
Pledged promoter(s) holding % 2.1 8.6 25.0%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare IPCA LABS With:   DIVIS LABORATORIES  WOCKHARDT  VENUS REMEDIES  FRESENIUS KABI ONCO.  GLENMARK PHARMA  

Compare IPCA LABS With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 154 Points Lower, Nifty Ends at 14,834; Bajaj Finance and UPL Among Top Losers(Closing)

Indian share markets witnessed volatile trading activity throughout the day today and ended marginally lower.

Related Views on News

IPCA LABS Announces Quarterly Results (3QFY21); Net Profit Up 32.2% (Quarterly Result Update)

Feb 5, 2021 | Updated on Feb 5, 2021

For the quarter ended December 2020, IPCA LABS has posted a net profit of Rs 3 bn (up 32.2% YoY). Sales on the other hand came in at Rs 13 bn (up 15.5% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

IPCA LABS Announces Quarterly Results (1QFY21); Net Profit Up 243.5% (Quarterly Result Update)

Sep 29, 2020 | Updated on Sep 29, 2020

For the quarter ended June 2020, IPCA LABS has posted a net profit of Rs 5 bn (up 243.5% YoY). Sales on the other hand came in at Rs 15 bn (up 46.9% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (1QFY21); Net Profit Up 25.6% (Quarterly Result Update)

Sep 15, 2020 | Updated on Sep 15, 2020

For the quarter ended June 2020, AUROBINDO PHARMA has posted a net profit of Rs 8 bn (up 25.6% YoY). Sales on the other hand came in at Rs 59 bn (up 8.8% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (4QFY20); Net Profit Up 48.2% (Quarterly Result Update)

Jun 5, 2020 | Updated on Jun 5, 2020

For the quarter ended March 2020, AUROBINDO PHARMA has posted a net profit of Rs 9 bn (up 48.2% YoY). Sales on the other hand came in at Rs 62 bn (up 16.4% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

IPCA LABS Announces Quarterly Results (3QFY20); Net Profit Up 22.8% (Quarterly Result Update)

Feb 17, 2020 | Updated on Feb 17, 2020

For the quarter ended December 2019, IPCA LABS has posted a net profit of Rs 2 bn (up 22.8% YoY). Sales on the other hand came in at Rs 11 bn (up 20.2% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

More Views on News

Most Popular

A Critical Update on the Market(Fast Profits Daily)

Mar 30, 2021

In this video, I'll tell you why I am recommending caution in the market at this time.

My Recent Recommendation Will Profit from the Global Supply Chain Crisis(Profit Hunter)

Mar 31, 2021

A tiny chemical company, started in the Licence Raj era, is a great example of a new wealth creating opportunity.

My Stock Trading Strategy(Fast Profits Daily)

Mar 31, 2021

In this video I'll show you exactly how I go about picking stocks for trading.

What You Need to Find Hundred Baggers(Profit Hunter)

Mar 30, 2021

100 baggers of the last decade share this common trait. Here's how to use it to nail future multibaggers.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

IPCA LABS SHARE PRICE


Apr 9, 2021 (Close)

TRACK IPCA LABS

  • Track your investment in IPCA LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE IPCA LABS WITH

MARKET STATS